Dr. Sam on Therapeutic Developments in Metastatic HER2+ Breast Cancer

Partner | Cancer Centers | <b>Moffitt</b>

Christine Sam, MD, discusses therapeutic developments in metastatic HER2-positive breast cancer.

Christine Sam, MD, assistant member, Department of Individualized Cancer Management/ Senior Adult Oncology Program, Moffitt Cancer Center, discusses therapeutic developmentsin metastatic HER2-positive breast cancer.

The treatment paradigm of HER2-positive breast cancer has grown considerably in recent years in both the early-stage and metastatic settings, Sam explains. In the metastatic setting, where there were significant unmet needs, tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu) represent welcome additions to the armamentarium, Sam adds.

Notably, tucatinib has demonstrated activity in terms of progression-free survival and overall survival benefit in patients with central nervous system (CNS) metastases. Prior to the phase 2 HER2CLIMB trial (NCT02614794) with tucatinib, clinical trials typically excluded patients with CNS involvement, Sam concludes.